1. 109 CLINICAL AND MOLECULAR PREDICTORS OF RESPONSE TO ERYTHROPOIESIS STIMULATING AGENTS (ESA) IN LOWER RISK MDS PATIENTS. (April 2015) Authors: Kosmider, O.; Passet, M.; Santini, V.; Platzbecker, U.; Andrieu, V.; Zini, G.; Beyne-Rauzy, O.; Guerci, A.; Slama, B.; Fenaux, P.; Dreyfus, F.; Fontenay, M.; Park, S. Journal: Leukemia research Issue: Volume 39(2015:Apr.) Supplement 1 Page Start: S56 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A Phase 3 Randomized Placebo (PBO)-Controlled Double-Blind Trial of Darbepoetin Alfa in Low or Intermediate-1 (INT-1) Risk Myelodysplastic Syndromes (MDS). (April 2017) Authors: Platzbecker, U.; Symeonidis, A.; Oliva, E.; Goede, J.; Delforge, M.; Mayer, J.; Slama, B.; Badre, S.; Gasal, E.; Mehta, B.; Franklin, J. Journal: Leukemia research Issue: Volume 55(2017)Supplement 1 Page Start: S29 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. A PHASE II STUDY OF LENALIDOMIDE AND RITUXIMAB (R²) COMBINATION IN PATIENTS WITH HIGH‐RISK REFRACTORY/RELAPSED DIFFUSE LARGE B‐CELL LYMPHOMA. (12th June 2019) Authors: Bouabdallah, R.; Zemmour, C.; Schiano de Collela, J.; Slama, B.; Bladé, J.; Belmecheri, N.; Coso, D.; Montes de Oca, C.; Stoppa, A.; Aurran‐Schleinitz, T.; Cournier, S.; Ivanov, V.; Mescam, L.; Blaise, D. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 433 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P1133: SUB-CUTANEOUS RITUXIMAB INDUCTION FOLLOWED BY SHORT RITUXIMAB MAINTENANCE IMPROVES PFS IN PATIENTS WITH LOW-TUMOR BURDEN FOLLICULAR LYMPHOMA. FINAL RESULTS OF FLIRT PHASE III TRIAL, A LYSA STUDY. (23rd June 2022) Authors: Cartron, G.; Bachy, E.; Tilly, H.; Daguindau, N.; Pica, G.-M.; Bijou, F.; Mounier, C.; Clavert, A. M.; Damaj, G. L.; Slama, B.; Casasnovas, O.; Houot, R.; Bouabdallah, K.; Sibon, D.; Fitoussi, O.; Morineau, N.; Herbaux, C.; Gastinne, T.; Fornecker, L.-M.; Haioun, C. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1023 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. P872: DEL(1P32) REMAINS A POWERFUL PROGNOSTIC FACTOR IN A LARGE COHORT OF NDMM PATIENTS: AN UPDATE. (23rd June 2022) Authors: Schavgoulidze, A.; Perrot, A.; Cazaubiel, T.; Leleu, X.; Manier, S.; Buisson, L.; Maheo, S.; Do Souto Ferreira, L.; Lannes, R.; Pavageau, L.; Hulin, C.; Marolleau, J.-P.; Voillat, L.; Belhadj, K.; Divoux, M.; Slama, B.; Brechignac, S.; Macro, M.; Stoppa, A.-M.; Sanhes, L. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 765 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. S169: CLINICAL AND MOLECULAR MARKERS FOR PREDICTING RESPONSE TO ROMIPLOSTIM TREATMENT IN LOWER-RISK MYELODYSPLASTIC SYNDROMES. (23rd June 2022) Authors: Kubasch, A. S.; Giagounidis, A.; Metzgeroth, G.; Jonasova, A.; Herbst, R.; Diaz, J. M. T.; De Renzis, B.; Götze, K. S.; Huetter-Kroenke, M.-L.; Gourin, M.-P.; Slama, B.; Dimicoli-Salazar, S.; Cony-Makhoul, P.; Laribi, K.; Park, S.; Jersemann, K.; Schipp, D.; Metzeler, K. H.; Tiebel, O.; Sockel, K. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 70 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Sintra-Rev Clinical Trial: Preliminary Analysis of Efficacy and Safety at Week 12 of Treatment in MDS Del(5Q) and Transfusion Independence. (April 2017) Authors: López Cadenas, F.; Xicoy, B.; Sánchez, J.; Fenaux, P.; Hernández Rivas, J.Á.; Amigo, M.L.; Coll, R.; Lumbreras, E.; Slama, B.; Bernal, T.; De Paz, R.; Platzbecker, U.; Giagounidis, A.; Nomdedeu, B.; Thepot, S.; Sanz, G.; Arrizabalaga, B.; Bargay, J.; Del Cañizo Fernández-Roldán, M.C.; Díez-Campel... Journal: Leukemia research Issue: Volume 55(2017)Supplement 1 Page Start: S52 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Topic: AS04-MDS Biology and Pathogenesis/AS04b-Clonal diversity & evolution: LONG-TERM MUTATIONAL DYNAMICS IN DEL(5Q) MDS PATIENTS EARLY TREATED WTIH LENALIDOMIDE (SINTRAREV CLINICAL TRIAL). SAFE AND EFFECITIVE APPROACH REGARDING CLONAL EVOLUTION?. (May 2023) Authors: Castelló, S.M. Toribio; López-Cadenas, F.; Preudhomme, C.; Ramiro, A. Villaverde; Fenwarth, L.; Lumbreras, E.; Gonzalez, T.; Del Rey, M.; Xicoy, B.; Renneville, A.; Sánchez, J.; Coll, R.; Slama, B.; Rivas, J.Á. Hernandez; Thépot, S.; Bernal, T.; Guerci-Bresler, A.; Götze, K.; Rivas, J.M. Hernande... Journal: Leukemia research Issue: Volume 128(2023)Supplement Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Treatment with Hizentra in patients with primary and secondary immunodeficiencies: a real-life, non-interventional trial. (December 2016) Authors: Viallard, J.; Agape, P.; Barlogis, V.; Cozon, G.; Faure, C.; Fouyssac, F.; Gaud, C.; Gourin, M.; Hamidou, M.; Hoarau, C.; Husseini, F.; Ojeda-Uribe, M.; Pavic, M.; Pellier, I.; Perlat, A.; Schleinitz, N.; Slama, B. Journal: BMC immunology Issue: Volume 17:Number 1(2016) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗